'%3e%3cg%20id='mkuqs0y719954117'%20opacity='1'%20style='mix-blend-mode:normal'%3e%3cg%3e%3cg%3e%3cg%20id='mkuqs0y821269793_translate'%3e%3cg%20transform='matrix(1,0,0,1,1.1796999999999969,1.1796999999999969)'%3e%3cg%20id='mkuqs0y821269793'%20opacity='1'%20style='mix-blend-mode:normal'%3e%3cg%3e%3cg%3e%3cpath%20id='mkuqs0y821269793_fill_path'%20d='M48.82031,0c13.86456,0.00003%2026.37902,5.77981%2035.26611,15.06104l-14.05957,14.93896c0,0%20-23.81334,-0.16351%20-27.38623,0c-3.57289,0.16351%20-6.41943,3.32226%20-6.41943,6.93555c0.00025,3.71799%203.01438,6.73193%206.73242,6.73193h11.1792c9.24095,0.00003%2016.73231,7.4915%2016.73242,16.73242c-0.00013,9.24091%20-7.49148,16.7324%20-16.73242,16.73242h-20.8335l-4.76758,4.79004c5.90399,3.62636%2012.85185,5.71826%2020.28857,5.71826c21.43975,-0.00005%2038.82026,-17.38057%2038.82031,-38.82031c0,-5.66398%20-1.21347,-11.04437%20-3.39404,-15.896l7.29443,-7.75049c3.88606,7.0057%206.09961,15.06749%206.09961,23.64648c-0.00005,26.96259%20-21.85772,48.82026%20-48.82031,48.82031c-26.96263,0%20-48.82026,-21.85769%20-48.82031,-48.82031c0,-26.96266%2021.85765,-48.82031%2048.82031,-48.82031zM48.82031,10c-21.43982,0%20-38.82031,17.3805%20-38.82031,38.82031c0.00002,10.38271%204.07608,19.81347%2010.71533,26.7793l8.42773,-8.46729h24.98975c3.71809,-0.00003%206.73229,-3.01435%206.73242,-6.73242c-0.00011,-3.71808%20-3.01432,-6.7324%20-6.73242,-6.73242h-11.1792c-9.24089,0%20-16.73217,-7.49111%20-16.73242,-16.73193c0,-9.24104%207.49138,-16.73242%2016.73242,-16.73242h23.97949l3.65186,-3.53223c-6.20753,-4.21062%20-13.69873,-6.67088%20-21.76465,-6.6709z'%20fill-rule='evenodd'%20fill='rgb(109,%20211,%20165)'%20fill-opacity='1'%20style='mix-blend-mode:normal'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3canimateTransform%20href='%23mkuqs0y821269793'%20attributeName='transform'%20type='translate'%20values='48.8203%2048.8203;48.8203%2048.8203;48.8203%2048.8203;48.8203%2048.8203'%20dur='1.3s'%20repeatCount='indefinite'%20calcMode='spline'%20keyTimes='0;0.51;0.99;1'%20keySplines='0.5%200.35%200.15%201;0.5%200.35%200.15%201;0.5%200.35%200.15%201'%20additive='sum'%20fill='freeze'%3e%3c/animateTransform%3e%3canimateTransform%20href='%23mkuqs0y821269793'%20attributeName='transform'%20type='scale'%20values='1%201;0.6%200.6;1%201;1%201'%20dur='1.3s'%20repeatCount='indefinite'%20calcMode='spline'%20keyTimes='0;0.51;0.99;1'%20keySplines='0.5%200.35%200.15%201;0.5%200.35%200.15%201;0.5%200.35%200.15%201'%20additive='sum'%20fill='freeze'%3e%3c/animateTransform%3e%3canimateTransform%20href='%23mkuqs0y821269793'%20attributeName='transform'%20type='translate'%20values='-48.8203%20-48.8203;-48.8203%20-48.8203;-48.8203%20-48.8203;-48.8203%20-48.8203'%20dur='1.3s'%20repeatCount='indefinite'%20calcMode='spline'%20keyTimes='0;0.51;0.99;1'%20keySplines='0.5%200.35%200.15%201;0.5%200.35%200.15%201;0.5%200.35%200.15%201'%20additive='sum'%20fill='freeze'%3e%3c/animateTransform%3e%3canimate%20href='%23mkuqs0y821269793'%20attributeName='opacity'%20values='1;0;1;1'%20dur='1.3s'%20repeatCount='indefinite'%20calcMode='spline'%20keyTimes='0;0.51;0.99;1'%20keySplines='0.5%200.35%200.15%201;0.5%200.35%200.15%201;0.5%200.35%200.15%201'%20additive='replace'%20fill='freeze'%3e%3c/animate%3e%3c/svg%3e)
Профиль компании
- Фондовый код
- VKTX
- Валюта
- US Dollar (USD)
- Дата IPO
- 2015-04-29
Viking Therapeutics Inc (VKTX)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients wit...
NASDAQHealthcareBiotechnologyUSA
Контактная информация
- Адрес компании
- 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121
- Контактный телефон
- 858 704 4660
- Веб-сайт компании
- https://www.vikingtherapeutics.com
- Конец финансового года
- December
Финансовые показатели
- Рыночная капитализация
- $999,999.99
- Валовая прибыль (ТТМ)
- $0
- Рентабельность активов (ТТМ)
- -51.86%
- Доход (ТТМ)
- $0